Related Experiment Videos

Respiratory syncytial virus immune globulin and conflict of interest

The New England Journal of Medicine

|December 29, 1998

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2003

Respiratory syncytial virus prophylaxis--the story so far.

Respiratory medicine·2002

Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.

The Pediatric infectious disease journal·2001

Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.

Antimicrobial agents and chemotherapy·1999

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.

The Journal of pediatrics·1998

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.

The Journal of infectious diseases·1998

See all related articles